Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel nanoformulation - Megapro Biomedical Company

Next Previous
Drug Profile

Cabazitaxel nanoformulation - Megapro Biomedical Company

Alternative Names: DMB025; MPB-1734

Latest Information Update: 24 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Megapro Biomedical Company
  • Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 14 Apr 2023 Adverse events and pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 08 Mar 2022 Phase-I/II clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in Taiwan (IV) (NCT04643418)
  • 25 Nov 2020 MegaPro Biomedical plans a phase I/IIa trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Taiwan in March 2021 (IV) (NCT04643418)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top